Liposome targeting following intravenous administration: Defining expectations and a need for improved methodology

被引:5
作者
Bally, MB [1 ]
Ansell, SM [1 ]
Tardi, PG [1 ]
Harasym, TO [1 ]
机构
[1] British Columbia Canc Agcy, Div Med Oncol, Vancouver, BC V5Z 4E6, Canada
基金
英国医学研究理事会;
关键词
D O I
10.3109/08982109709035507
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The prospects for developing improved liposome based anti-cancer drug formulations are great, particularly when considering the potential role of lipid-based formulations for delivery of biopharmaceuticals. It is important however, to pursue improved formulations with an expectation of what the improvements are designed to achieve and an understanding of the pharmaceutical issues involved in development of such a drug. Our efforts in this area have focused on the important role of liposome extravasation in defining therapeutic activity of intravenously administered liposomal anticancer drugs. We have developed targeting strategies based on two key assumptions. First, cell specific targeting is an attribute required after the passive extravasation of a drug-loaded carrier. Accordingly, if targeting is to be of potential therapeutic value it is important that the targeting features do not Interfere with the tendency of the carrier to move from the blood compartment to an extravascular site. Second, it is critical to demonstrate that liposomes that have extravasated are available for targeting. As part of this effort we have identified a need to develop simple, pharmaceutically viable, procedures for the preparation of stable protein conjugated liposomes.
引用
收藏
页码:331 / 361
页数:31
相关论文
共 88 条
[1]  
AHMAD I, 1993, CANCER RES, V53, P1484
[2]  
Allen Theresa M., 1994, Journal of Liposome Research, V4, P1, DOI 10.3109/08982109409037027
[3]   UPTAKE OF LIPOSOMES BY CULTURED MOUSE BONE-MARROW MACROPHAGES - INFLUENCE OF LIPOSOME COMPOSITION AND SIZE [J].
ALLEN, TM ;
AUSTIN, GA ;
CHONN, A ;
LIN, L ;
LEE, KC .
BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1061 (01) :56-64
[4]   LIPOSOMES CONTAINING SYNTHETIC LIPID DERIVATIVES OF POLY(ETHYLENE GLYCOL) SHOW PROLONGED CIRCULATION HALF-LIVES INVIVO [J].
ALLEN, TM ;
HANSEN, C ;
MARTIN, F ;
REDEMANN, C ;
YAUYOUNG, A .
BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1066 (01) :29-36
[5]   3-(2-pyridyldithio)propionic acid hydrazide as a cross-linker in the formation of liposome-antibody conjugates [J].
Ansell, SM ;
Tardi, PG ;
Buchkowsky, SS .
BIOCONJUGATE CHEMISTRY, 1996, 7 (04) :490-496
[6]   IMMUNE CLEARANCE OF LIPOSOMES INHIBITED BY AN ANTI-FC RECEPTOR ANTIBODY INVIVO [J].
ARAGNOL, D ;
LESERMAN, LD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (08) :2699-2703
[7]  
BALAZSOVITS JAE, 1989, CANCER CHEMOTH PHARM, V23, P81
[8]  
Bally M. B., 1988, LIPOSOMES DRUG CARRI, P841
[9]   TRANSFER OF LIPOSOMAL DRUG CARRIERS FROM THE BLOOD TO THE PERITONEAL-CAVITY OF NORMAL AND ASCITIC TUMOR-BEARING MICE [J].
BALLY, MB ;
MASIN, D ;
NAYAR, R ;
CULLIS, PR ;
MAYER, LD .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1994, 34 (02) :137-146
[10]   LIPOSOMES WITH ENTRAPPED DOXORUBICIN EXHIBIT EXTENDED BLOOD RESIDENCE TIMES [J].
BALLY, MB ;
NAYAR, R ;
MASIN, D ;
HOPE, MJ ;
CULLIS, PR ;
MAYER, LD .
BIOCHIMICA ET BIOPHYSICA ACTA, 1990, 1023 (01) :133-139